1298 Prospect Street
Suite 2A
Cebix Inc.
Cebix Inc. is developing a disease-modifying replacement peptide for complications associated with diabetes. Unlike other products simply directed at symptomatic relief, Cebix thinks its long-acting form of C-peptide has the potential to reverse the chronic complications of diabetes.
More from Archive
More from Scrip
• By
Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.
• By
Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.
• By
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.